BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 5, 2019--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of
Ocular Therapeutix, will present at the Cowen and Company 39th Annual
Health Care Conference on Wednesday, March 13, 2019 at 8:40 AM ET at the
Boston Marriott Copley Place Hotel in Boston, MA.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their Cowen and Company representative.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation, development,
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable hydrogel-based
formulation technology. Ocular Therapeutix’s first commercial drug
product, DEXTENZA®, is FDA-approved for the treatment of ocular pain
following ophthalmic surgery. OTX-TP (intracanalicular travoprost
insert) is an intracanalicular insert in Phase 3 clinical development
for the reduction of intraocular pressure in patients with primary
open-angle glaucoma and ocular hypertension. The Company’s earlier stage
assets include OTX-TIC, an extended-delivery intracameral travoprost
implant for the reduction of intraocular pressure in patients with
glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include OTX-TKI, containing a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005189/en/
Source: Ocular Therapeutix, Inc.
Chris Brinzey, 339-970-2843